IL141064A0 - Tnf-derived peptides for use in treating oedema - Google Patents

Tnf-derived peptides for use in treating oedema

Info

Publication number
IL141064A0
IL141064A0 IL14106499A IL14106499A IL141064A0 IL 141064 A0 IL141064 A0 IL 141064A0 IL 14106499 A IL14106499 A IL 14106499A IL 14106499 A IL14106499 A IL 14106499A IL 141064 A0 IL141064 A0 IL 141064A0
Authority
IL
Israel
Prior art keywords
tnf
oedema
alpha
present
derived peptides
Prior art date
Application number
IL14106499A
Other languages
English (en)
Original Assignee
Innogenetics Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics Nv filed Critical Innogenetics Nv
Publication of IL141064A0 publication Critical patent/IL141064A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/191Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/525Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL14106499A 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema IL141064A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21
PCT/EP1999/005806 WO2000009149A1 (en) 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema

Publications (1)

Publication Number Publication Date
IL141064A0 true IL141064A0 (en) 2002-02-10

Family

ID=27239778

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14106499A IL141064A0 (en) 1998-08-14 1999-08-10 Tnf-derived peptides for use in treating oedema
IL141064A IL141064A (en) 1998-08-14 2001-01-24 Use of tnf-derived peptides for the manufacture of a medicament for treating oedema

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL141064A IL141064A (en) 1998-08-14 2001-01-24 Use of tnf-derived peptides for the manufacture of a medicament for treating oedema

Country Status (20)

Country Link
US (2) US20030105021A1 (https=)
EP (3) EP1264599B1 (https=)
JP (1) JP4542266B2 (https=)
CN (1) CN1181886C (https=)
AT (2) ATE374039T1 (https=)
AU (1) AU764992B2 (https=)
BR (1) BR9912899A (https=)
CA (1) CA2334941C (https=)
CZ (1) CZ302862B6 (https=)
DE (2) DE69938743D1 (https=)
DK (1) DK1264599T3 (https=)
ES (1) ES2296872T3 (https=)
HU (1) HU227661B1 (https=)
IL (2) IL141064A0 (https=)
NZ (1) NZ509604A (https=)
PL (1) PL203706B1 (https=)
PT (1) PT1264599E (https=)
TR (1) TR200100338T2 (https=)
WO (1) WO2000009149A1 (https=)
ZA (1) ZA200100656B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema
CA2575513C (en) * 2004-08-06 2014-09-16 Altana Pharma Ag Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) * 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) * 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
PL2397151T3 (pl) * 2010-06-21 2015-10-30 Apeptico Forschung & Entwicklung Gmbh Leczenie powikłań naczyniowych cukrzycy
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US20160143266A1 (en) * 2013-04-23 2016-05-26 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical Composition Comprising a Cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
US10925924B2 (en) 2014-03-18 2021-02-23 Apeptico Forschung Und Entwicklung Gmbh Dry-powder peptide medicament
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115461356A (zh) 2020-05-08 2022-12-09 阿佩普蒂科研究和开发有限责任公司 用于预防或治疗covid-19的肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) * 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
EP1264599B1 (en) 1998-08-14 2007-09-26 Rudolf Lucas TNF-derived peptides for use in treating oedema

Also Published As

Publication number Publication date
US20030105021A1 (en) 2003-06-05
CZ302862B6 (cs) 2011-12-21
CN1312724A (zh) 2001-09-12
AU5620999A (en) 2000-03-06
HK1051805A1 (en) 2003-08-22
IL141064A (en) 2009-09-01
ATE395072T1 (de) 2008-05-15
ZA200100656B (en) 2005-06-29
PT1264599E (pt) 2008-01-07
HUP0103117A2 (hu) 2001-12-28
CZ2001538A3 (cs) 2001-08-15
EP1247531A2 (en) 2002-10-09
ES2296872T3 (es) 2008-05-01
EP1247531A3 (en) 2002-12-18
EP1264599A1 (en) 2002-12-11
NZ509604A (en) 2003-05-30
CA2334941C (en) 2011-08-09
DK1264599T3 (da) 2008-02-04
CA2334941A1 (en) 2000-02-24
ATE374039T1 (de) 2007-10-15
WO2000009149A1 (en) 2000-02-24
DE69937206T2 (de) 2008-06-19
EP1264599B1 (en) 2007-09-26
PL345997A1 (en) 2002-01-14
DE69938743D1 (de) 2008-06-26
DE69937206D1 (de) 2007-11-08
EP1105152A1 (en) 2001-06-13
HU227661B1 (hu) 2011-10-28
AU764992B2 (en) 2003-09-04
US7258861B2 (en) 2007-08-21
JP2002522508A (ja) 2002-07-23
EP1247531B1 (en) 2008-05-14
PL203706B1 (pl) 2009-11-30
CN1181886C (zh) 2004-12-29
US20030185791A1 (en) 2003-10-02
HUP0103117A3 (en) 2004-03-01
BR9912899A (pt) 2001-05-08
JP4542266B2 (ja) 2010-09-08
TR200100338T2 (tr) 2001-12-21

Similar Documents

Publication Publication Date Title
IL141064A0 (en) Tnf-derived peptides for use in treating oedema
HU902697D0 (en) Process for the enzymatic removal of the n-terminal sequence of proteins
IL161591A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
AU2672900A (en) Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides
IL187907A0 (en) Analogues of glp-1 and uses thereof
IL143481A0 (en) Glp-1 analogues
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
JP2001520045A5 (https=)
EP0188400A3 (en) Oligopeptides, intermediates and process for their preparation
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
WO2002015922A3 (en) New uses for amino acid anticonvulsants for treatment of pain
DE60217326D1 (de) Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
GB2367061A (en) Peptides
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
EP0318935A3 (en) Substituted alpha-amino acids having pharmaceutical activity
DE69329899D1 (de) Behandlung von tropikalischer spastischer Paresis mit Peptide T
DE69524415D1 (de) UNGESPLEISSTE VARIANTEN DES gp350/220
DE69734644D1 (de) Carboxypeptidasen aus aspergillus oryzae und diese kodierende nukleinsäuren
WO1996003122A3 (en) Use of gabapentin in the treatment of anxiety and panic
GB9604518D0 (en) Novel compounds